Novavax Raises Full-Year Revenue Guidance Following Q3 Earnings Beat
Novavax (NVAX) shares saw upward momentum in premarket trading following a third-quarter earnings report that exceeded analyst expectations. The biotechnology company reported quarterly revenue of $68.3 million, driven primarily by increased product sales. In response to the strong performance, Novavax has raised its full-year revenue outlook. This guidance adjustment reflects management's confidence in sustained demand for its COVID-19 vaccine products and improved financial momentum heading into the end of the fiscal year.
Tickers: $NVAX
Topics: biotech COVID-19 vaccine earnings report revenue guidance